Initially designed to target the published CDC and WHO consensus sequences, the AccuPlex SARS-CoV-2 Verification Panel and Reference Material Kit are available with full SARS-CoV-2 viral genome coverage.
This expansion allows for compatibility with any SARS-CoV-2 assay target, while maintaining the safety features and performance monitoring advantages of AccuPlex technology.
LGC’s proprietary AccuPlex technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient. These materials serve as true, full-process, quality solutions that challenge the entire PCR test procedure, making them the preferred alternative to infectious materials. Together, the AccuPlex SARS-CoV-2 Verification Panel and AccuPlex SARS-CoV-2 Reference Material Kit offer an ideal solution for clinical laboratories looking for a safe, effective tool to verify and monitor SARS-CoV-2 molecular assay performance.
Michael Sweatt, Executive Vice President, LGC SeraCare, stated: “We are proud to continue to expand our SARS-CoV-2 product offering to adapt to the evolving needs of the diagnostic community. Our full genome AccuPlex products are just the latest innovations in our line of SARS-CoV-2 molecular and serology quality solutions designed to support early detection of infection and antibody surveillance efforts throughout the ongoing COVID-19 pandemic.”
